AU723315B2 - Combination therapy for reducing the risks associated with cardiovascular disease - Google Patents

Combination therapy for reducing the risks associated with cardiovascular disease Download PDF

Info

Publication number
AU723315B2
AU723315B2 AU43508/97A AU4350897A AU723315B2 AU 723315 B2 AU723315 B2 AU 723315B2 AU 43508/97 A AU43508/97 A AU 43508/97A AU 4350897 A AU4350897 A AU 4350897A AU 723315 B2 AU723315 B2 AU 723315B2
Authority
AU
Australia
Prior art keywords
hmg
inhibitor
coa reductase
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43508/97A
Other languages
English (en)
Other versions
AU4350897A (en
Inventor
Robert J. Gould
Steven A. Nichtberger
Lars Olofsson
Patricia A. Rhymer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621970.4A external-priority patent/GB9621970D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU4350897A publication Critical patent/AU4350897A/en
Application granted granted Critical
Publication of AU723315B2 publication Critical patent/AU723315B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU43508/97A 1996-09-18 1997-09-15 Combination therapy for reducing the risks associated with cardiovascular disease Ceased AU723315B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2658196P 1996-09-18 1996-09-18
US60/026581 1996-09-18
GBGB9621970.4A GB9621970D0 (en) 1996-10-22 1996-10-22 Combination therapy for reducing the risks associated with cardiovascular disease
GB9621970 1996-10-22
PCT/US1997/016388 WO1998011896A1 (fr) 1996-09-18 1997-09-15 Traitement combine destine a reduire les risques de maladies cardio-vasculaires

Publications (2)

Publication Number Publication Date
AU4350897A AU4350897A (en) 1998-04-14
AU723315B2 true AU723315B2 (en) 2000-08-24

Family

ID=26310268

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43508/97A Ceased AU723315B2 (en) 1996-09-18 1997-09-15 Combination therapy for reducing the risks associated with cardiovascular disease

Country Status (5)

Country Link
EP (1) EP0946178A4 (fr)
JP (1) JP2001500875A (fr)
AU (1) AU723315B2 (fr)
CA (1) CA2265827A1 (fr)
WO (1) WO1998011896A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4588877B2 (ja) 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Ａｄｐ−受容体抗血小板物質と抗高血圧薬の組合せ投与による脳梗塞の予防
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
DK1176956T3 (da) * 1999-05-07 2008-05-26 Encysive Pharmaceuticals Inc Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
WO2001021259A2 (fr) * 1999-09-21 2001-03-29 Emory University Procedes et compositions de traitement des pathologies apparentees aux plaquettes
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
DK1272220T4 (en) * 2000-04-10 2016-11-28 Nicholas John Wald Cardiovascular disease prevention formulation
US20020048599A1 (en) * 2000-10-20 2002-04-25 Thomas H. Mueller Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2004080488A2 (fr) * 2003-03-10 2004-09-23 Bayer Healthcare Ag Preparations combinees d'acide acetylsalycilique pour la prevention primaire de maladies cardiovasculaires
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
GB0307715D0 (en) 2003-04-03 2003-05-07 Ethicon Endo Surgery Inc Guide wire structure for insertion into an internal space
US8070693B2 (en) 2004-09-30 2011-12-06 Cook Medical Technologies Llc Articulating steerable wire guide
US7598233B2 (en) * 2005-03-28 2009-10-06 Kowa Co., Ltd. Method for treating thrombosis
ES2378896T3 (es) 2005-09-15 2012-04-18 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos que contiene Probucol y un derivado de tetrazolilalcoxi-dihidrocarbostirilo con efectos inhibidores del superóxido
US8715205B2 (en) 2006-08-25 2014-05-06 Cook Medical Tecnologies Llc Loop tip wire guide
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
LV14963B (lv) 2013-06-28 2015-10-20 Tetra, Sia Endoteliālās disfunkcijas korektors
EP4403138A3 (fr) 2015-05-01 2024-10-09 JenaValve Technology, Inc. Dispositif et procédé avec fréquence de stimulateur cardiaque réduite lors du remplacement de valvule cardiaque

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
HUT68769A (en) * 1991-05-07 1995-07-28 Merck & Co Inc FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE
EP0904082A4 (fr) * 1996-04-17 2001-09-26 Merck & Co Inc Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire

Also Published As

Publication number Publication date
EP0946178A4 (fr) 2003-05-07
AU4350897A (en) 1998-04-14
CA2265827A1 (fr) 1998-03-26
EP0946178A1 (fr) 1999-10-06
WO1998011896A1 (fr) 1998-03-26
JP2001500875A (ja) 2001-01-23

Similar Documents

Publication Publication Date Title
AU723315B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US6403571B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US6511968B1 (en) Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
US6251852B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
RU2262933C2 (ru) Медицинские композиции, содержащие аспирин
RU2252783C2 (ru) Фармацевтический препарат, содержащий низкомолекулярный ингибитор тромбина и его пролекарство
WO1997035579A1 (fr) Procede d'inhibition de la formation de caillots
EP1061908A1 (fr) Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
US6518244B2 (en) Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
AU766089B2 (en) Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin
AU740941B2 (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6136794A (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
JPH03153633A (ja) ２型糖尿病の予防用薬剤
US6794412B1 (en) Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US5978698A (en) Angioplasty procedure using nonionic contrast media
WO1997035615A1 (fr) Compositions et techniques d'inhibition de la formation de caillots
US6566361B2 (en) Azapirone pain treatment
US5900414A (en) Methods for administering integrin receptor antagonists
KR100251622B1 (ko) 피브리노겐 수용체 길항물질 및 전기물질을 유효성분으로 하는 의약제제
MXPA01009080A (en) Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
WO2001076587A1 (fr) Remedes aux maladies associees aux lesions stenosees de vaisseaux sanguins
AU4086297A (en) Compositions and methods for administering integrin receptor antagonists
GB2318053A (en) Angioplasty procedure using nonionic contrast media

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTORS BY DELETING P A RHYMER AND L OLOFSSON